ClearBridge Investments’s Heron Therapeutics HRTX Stock Holding History

ClearBridge Investments’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,436,925	Closed	-$55.7M	–	841
2021 Q1	$55.7M	Sell	3,436,925 -17,281	-0.5%	-$308K	0.04%	335
2020 Q4	$73.1M	Buy	3,454,206 +18,181	+0.5%	+$316K	0.06%	263
2020 Q3	$50.9M	Sell	3,436,025 -2,587	-0.1%	-$40.4K	0.04%	286
2020 Q2	$50.6M	Buy	3,438,612 +12,532	+0.4%	+$206K	0.05%	269
2020 Q1	$40.2M	Sell	3,426,080 -23,364	-0.7%	-$439K	0.04%	273
2019 Q4	$79.9M	Sell	3,449,444 -794	-0%	-$17.6K	0.07%	233
2019 Q3	$63.8M	Buy	3,450,238 +739,663	+27%	+$13.6M	0.06%	272
2019 Q2	$50.4M	Buy	2,710,575 +529,998	+24%	+$10.6M	0.04%	317
2019 Q1	$53.3M	Buy	2,180,577 +1,320,025	+153%	+$34.6M	0.05%	300
2018 Q4	$22.3M	Buy	+860,552	New	+$23.7M	0.02%	409

Other funds holding HRTX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments's HRTX Position: Q2 2021 in Review

ClearBridge Investments sold out of Heron Therapeutics (HRTX) in Q2 2021, closing a stake of 3,436,925 shares — an estimated $55.7M sold.

ClearBridge Investments first reported a position in HRTX in Q4 2018 and held it in 10 quarters. The position peaked at $79.9M in Q4 2019. 189 funds tracked by Wall St. Rank hold HRTX as of Q2 2021.

ClearBridge Investments reported no remaining Heron Therapeutics position as of Q2 2021 after selling out during the quarter.
ClearBridge Investments sold 3,436,925 Heron Therapeutics shares in Q2 2021, an estimated $55.7M.
ClearBridge Investments first reported a position in Heron Therapeutics in Q4 2018 and held it in 10 quarters.
ClearBridge Investments's Heron Therapeutics position peaked at $79.9M in Q4 2019.
189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2021.

Based on ClearBridge Investments's 13F filing for Q2 2021, filed 13 Aug 2021.